PTCT NASDAQ
PTC Therapeutics, Inc.
1W: -1.3%
1M: -5.8%
3M: -16.6%
YTD: -19.1%
1Y: -6.5%
3Y: +167.5%
5Y: +71.2%
$62.09
+1.02 (+1.67%)
Weekly Expected Move ±5.7%
$54
$57
$61
$64
$68
Credit Risk of going bust: lower than 68% of companies Debt: 11.8% of company value Bonds: $48.8M held by 18 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.66 (down 99%), PTC Therapeutics, Inc. would be worth roughly what it owes.
Total debt $696.5M against a stock market value of $5.18B.
Distance to default 7.32 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $323.2M (short-term plus half of long-term), stock volatility 40.6%; Altman Z'' 1.03. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.66 (down 99%), PTC Therapeutics, Inc. would be worth roughly what it owes.
Total debt $696.5M against a stock market value of $5.18B.
Distance to default 7.32 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $323.2M (short-term plus half of long-term), stock volatility 40.6%; Altman Z'' 1.03. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.45
Bearish
0 bullish
1 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (97)
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
PTC Therapeutics (NASDAQ:PTCT) Director Sells $149,025.00 in Stock
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 435 Shares of Company Stock
PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Glenn Md Phd Steele, Jr. Sells 12,000 Shares
PTC Therapeutics (NASDAQ:PTCT) Shares Climb 4.7% – Here’s Why
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
Amundi Raises Holdings in PTC Therapeutics, Inc. $PTCT
California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT
PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTC Therapeutics, Inc. $PTCT Shares Sold by Arrowstreet Capital Limited Partnership
Dimensional Fund Advisors LP Purchases 263,623 Shares of PTC Therapeutics, Inc. $PTCT
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
PTC Therapeutics, Inc. $PTCT Shares Purchased by Fifth Third Bancorp
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
PTC Therapeutics, Inc. $PTCT Shares Purchased by Bessemer Group Inc.
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
Reasons Why Investors Should Consider Betting on PTC Stock Now
Immunome Stock Up 32% in a Month: Here's What You Should Know
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
Agilent Strengthens Biopharma Growth Prospects With AI Expansion
Stocks Look Shaky, But This Sector is Booming (Biotech)
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
12 Health Care Stocks Moving In Friday's Intraday Session
PTC Therapeutics climbs after guidance hike
PTCT Q1 2026 Earnings Transcript
PTC outlines 2026 product revenue guidance of $750M-$850M driven by Sephience launch momentum
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT
PTC Therapeutics, Inc. $PTCT Shares Sold by Choreo LLC
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
KROS Rinvatercept: What to Know Before DMD Phase II Starts
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
Burney Co. Takes Position in PTC Therapeutics, Inc. $PTCT
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 829 Shares
Phocas Financial Corp. Has $1.94 Million Stock Position in PTC Therapeutics, Inc. $PTCT
Neil Gregory Almstead Sells 52,003 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics, Inc. $PTCT Shares Sold by Empirical Financial Services LLC d.b.a. Empirical Wealth Management
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of “Moderate Buy” from Analysts
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT
KROS Stock: What to Know About Rinvatercept in DMD
KROS: Is the Discount Book Value a Value Trap?
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Matthew Klein Sells 7,371 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB
PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Analysts
Universal Beteiligungs und Servicegesellschaft mbH Has $8.11 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT
Campbell & CO Investment Adviser LLC Has $205,000 Stock Position in PTC Therapeutics, Inc. $PTCT
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells $164,596.05 in Stock
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $233,679.68 in Stock
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 8,089 Shares of Stock
Eric Pauwels Sells 20,508 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A.
Eric Pauwels Sells 40,290 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000
Bank of New York Mellon Corp Acquires 49,728 Shares of PTC Therapeutics, Inc. $PTCT